Neuronetics, Inc. (NASDAQ:STIM) CFO Sells $48,662.08 in Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 14,836 shares of Neuronetics stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.28, for a total transaction of $48,662.08. Following the completion of the transaction, the chief financial officer now directly owns 482,572 shares in the company, valued at approximately $1,582,836.16. This trade represents a 2.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Stephen Furlong also recently made the following trade(s):

• On Wednesday, February 12th, Stephen Furlong sold 10,845 shares of Neuronetics stock. The stock was sold at an average price of $3.83, for a total transaction of $41,536.35.

Neuronetics Stock Performance

Shares of Neuronetics stock opened at $4.36 on Friday. The stock has a market cap of $132.33 million, a PE ratio of -3.54 and a beta of 2.17. Neuronetics, Inc. has a 12 month low of $0.52 and a 12 month high of $5.07. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The business has a fifty day simple moving average of $2.20 and a 200-day simple moving average of $1.42.

Institutional Trading of Neuronetics

Several institutional investors have recently made changes to their positions in STIM. GSA Capital Partners LLP increased its stake in shares of Neuronetics by 64.5% in the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after acquiring an additional 30,837 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in Neuronetics in the third quarter valued at about $53,000. HighTower Advisors LLC increased its position in Neuronetics by 55.5% in the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after purchasing an additional 87,816 shares during the last quarter. David J Yvars Group raised its stake in shares of Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock worth $75,000 after purchasing an additional 14,825 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Neuronetics by 10,954.1% during the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after buying an additional 54,442 shares during the last quarter. 53.59% of the stock is currently owned by institutional investors and hedge funds.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.